Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07225946 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

Study acronym: KLK2-PASenger
StatusRecruiting
PhasePhase 3
Started2025-12-19
View on ClinicalTrials.gov ↗
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans or death due to any cause) when compared to treatment with docetaxel in participants with metastatic castrate-resistant prostate cancer (mCRPC; a cancer of prostate, a male reproductive gland found below the bladder, that grows despite low levels of male hormones).

Amendment history 5 changes detected by DataLookout

2026-07-31
Primary endpoint(s) modified
WasRadiographic Progression-Free Survival (rPFS) Assessed by BICR
NowRadiographic Progression-Free Survival (rPFS) by computed tomography (CT)/magnetic resonance imaging (MRI) or bone scan Assessed by Blinded Independent Central Review (BICR)
2026-07-31
Trial sites expanded: 136 → 150 locations
2026-06-06
Trial sites expanded: 117 → 136 locations
2026-05-12
Trial sites expanded: 97 → 117 locations
2026-04-15
Trial sites expanded: 53 → 97 locations
Trial Details
NCT Number NCT07225946
Lead Sponsor Janssen Research & Development, LLC
Conditions Prostatic Neoplasms, Castration-Resistant
Enrollment 800 participants
Start Date 2025-12-19
Primary Completion 2027-11-19 (estimated)
Study Completion 2029-07-20 (estimated)
Updated on ClinicalTrials.gov 2026-08-28